thalidomide has been researched along with Carcinoma, Squamous Cell in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was initiated at 200 mg;3>daily and increased to a target dose of 1000 mg daily." | 2.70 | Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. ( Abbruzzese, JL; El-Naggar, AK; Ginsberg, LE; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Lawhorn, KN; Myers, JN; Pluda, JM; Roach, JS; Shin, DM; Steinhaus, GD; Teddy, S; Thall, PF; Tseng, JE; Wang, X; Zentgraf, RE, 2001) |
| "Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors." | 1.35 | Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. ( Ge, JP; Yang, Y; Zhou, ZT, 2009) |
| "Thalidomide is an immunomodulatory, antiangiogenic drug." | 1.34 | Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. ( Beckhove, P; Dyckhoff, G; Helmke, BM; Herold-Mende, CC; Kashfi, F; Lemke, B; Lohr, J; Plinkert, PK; Schirrmacher, V; Vasvari, GP, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharman, JP | 1 |
| Chmielecki, J | 1 |
| Morosini, D | 1 |
| Palmer, GA | 1 |
| Ross, JS | 1 |
| Stephens, PJ | 1 |
| Stafl, J | 1 |
| Miller, VA | 1 |
| Ali, SM | 1 |
| Taylor, RJ | 1 |
| Saloura, V | 1 |
| Jain, A | 1 |
| Goloubeva, O | 1 |
| Wong, S | 1 |
| Kronsberg, S | 1 |
| Nagilla, M | 1 |
| Silpino, L | 1 |
| de Souza, J | 1 |
| Seiwert, T | 1 |
| Vokes, E | 1 |
| Villaflor, V | 1 |
| Cohen, EE | 1 |
| Yang, Y | 2 |
| Ge, JP | 2 |
| Zhou, ZT | 1 |
| Zhu, YQ | 1 |
| Jiang, L | 1 |
| Li, LF | 1 |
| Di Lucca-Christment, J | 1 |
| Jacobelli, S | 1 |
| Gressier, L | 1 |
| Plantier, F | 1 |
| Laude, H | 1 |
| Rozenberg, F | 1 |
| Rosenberg, F | 1 |
| Morini, JP | 1 |
| Dallot, A | 1 |
| Avril, MF | 1 |
| Dupin, N | 1 |
| Porter, SR | 1 |
| Jorge, J | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Morris, TC | 1 |
| Vasvari, GP | 1 |
| Dyckhoff, G | 1 |
| Kashfi, F | 1 |
| Lemke, B | 1 |
| Lohr, J | 1 |
| Helmke, BM | 1 |
| Schirrmacher, V | 1 |
| Plinkert, PK | 1 |
| Beckhove, P | 1 |
| Herold-Mende, CC | 1 |
| Myoung, H | 1 |
| Hong, SD | 1 |
| Kim, YY | 1 |
| Hong, SP | 1 |
| Kim, MJ | 1 |
| Tseng, JE | 1 |
| Glisson, BS | 1 |
| Khuri, FR | 1 |
| Shin, DM | 1 |
| Myers, JN | 1 |
| El-Naggar, AK | 1 |
| Roach, JS | 1 |
| Ginsberg, LE | 1 |
| Thall, PF | 1 |
| Wang, X | 1 |
| Teddy, S | 1 |
| Lawhorn, KN | 1 |
| Zentgraf, RE | 1 |
| Steinhaus, GD | 1 |
| Pluda, JM | 1 |
| Abbruzzese, JL | 1 |
| Hong, WK | 1 |
| Herbst, RS | 1 |
1 review available for thalidomide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Thalidomide: a role in oral oncology?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Mouth Neoplasms; N | 2002 |
2 trials available for thalidomide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Squamous C | 2001 |
7 other studies available for thalidomide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Carcino | 2009 |
Thalidomide induces apoptosis in human oral squamous cell carcinoma cell line with altered expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Topics: Apoptosis; Carcinoma, Squamous Cell; Humans; Immunosuppressive Agents; Mouth Neoplasms; Thalidomide; | 2011 |
Anogenital pseudotumoral herpes and HIV infection: a new challenge for diagnosis and treatment.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Carcinoma, Squamous Cell; Cidofovir; | 2012 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |
Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2007 |
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug | 2001 |